Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials.
Boos
C J
CJ
Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK. christopherboos@hotmail.com
Lip
G Y H
GY
D057912:Angiotensin II Type 2 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000503:physiopathology*; D012084:Renin-Angiotensin System
D057912:Angiotensin II Type 2 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents